A triple cognitive-metabolic blend combining synaptogenesis, triple monoamine reuptake inhibition, and mitochondrial support.
This advanced capsule combines three distinct compounds that address cognitive performance from complementary angles: Dihexa (a potent synaptogenesis promoter via HGF/c-Met signaling), Tesofensine (a triple monoamine reuptake inhibitor originally developed for Parkinson’s and Alzheimer’s disease), and Methylene Blue (a century-old mitochondria-targeting electron carrier). Dihexa was developed at Washington State University and has been reported to be approximately 10 million times more potent than BDNF at promoting synapse formation in the hippocampus. Tesofensine achieved the highest weight loss ever reported for an oral drug in Phase II obesity trials (10.6% body weight reduction), while also demonstrating significant cognitive enhancement through dopaminergic and noradrenergic mechanisms. Methylene Blue has been used in medicine since the 1890s and has demonstrated cognitive enhancement in multiple human studies by improving mitochondrial electron transport chain efficiency. Together, these three compounds provide structural brain enhancement (Dihexa), neurotransmitter optimization (Tesofensine), and cellular energy improvement (Methylene Blue) in a single capsule.
* Benefits based on preclinical/animal research unless otherwise noted.
Dihexa promotes synaptogenesis by binding to HGF (hepatocyte growth factor) and potentiating its interaction with the c-Met receptor, activating PI3K/Akt and MAPK/ERK cascades that drive dendritic spine growth and synapse formation. Tesofensine inhibits the reuptake transporters for dopamine (DAT), serotonin (SERT), and norepinephrine (NET), increasing synaptic concentrations of all three monoamines simultaneously — providing enhanced focus, motivation, and appetite suppression through central mechanisms. Methylene Blue acts as a redox cycler in the mitochondrial electron transport chain, accepting electrons from NADH and donating them to cytochrome c to bypass Complex I/III dysfunction, improving ATP production and reducing reactive oxygen species. The combination provides synergistic cognitive enhancement through three non-overlapping mechanisms: structural (synaptogenesis), neurotransmitter (monoamine reuptake inhibition), and bioenergetic (mitochondrial optimization).
Protocol Notes: Morning dosing only — stimulant effects may disrupt sleep. Avoid with MAOIs or serotonergic drugs (Tesofensine serotonin syndrome risk).
Store at room temperature, away from light.
When sourcing Dihexa + Tesofensine + Methylene Blue (Capsule) for research purposes, the following quality benchmarks should be verified before use.
Store at room temperature, away from light.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Preliminary Evidence — Early-stage research only. Significant uncertainty about efficacy and safety in humans.
Peptides commonly used alongside Dihexa + Tesofensine + Methylene Blue (Capsule) for synergistic effects.
Dopaminergic Nootropic + Mitochondrial Support
A powerful dopaminergic nootropic combined with a mitochondria-targeting electron carrier for enhanced cognitive function.
Learn More: 9-ME-BC + Methylene Blue (Capsule)Angiotensin IV Analog / Nootropic
An angiotensin IV analog reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
Learn More: Dihexa (Capsule)